Jun 4, 2026 06:44AM
May 7, 2026 04:30PM
Mar 16, 2026 06:53AM
Mar 12, 2026 04:01PM
Jan 12, 2026 08:00AM
Dec 19, 2025 08:00AM
Dec 19, 2025 08:00AM IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
Nov 6, 2025 04:00PM
Oct 27, 2025 08:00AM
Oct 13, 2025 06:42AM
Jun 2, 2025 07:30AM
Jun 2, 2025 07:30AM
Mar 13, 2025 04:05PM
Feb 14, 2025 09:00AM IN8bio, Inc (INAB) Presents Positive Phase 1 Data at TCT 2025
Feb 14, 2025 09:00AM
Nov 12, 2024 04:26PM
Sep 4, 2024 04:02PM
Sep 4, 2024 04:01PM
Aug 12, 2024 08:06AM
Aug 12, 2024 08:05AM
Jun 13, 2024 04:01PM IN8bio, Inc (INAB) Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
Jun 13, 2024 04:01PM
Apr 30, 2024 06:05AM
Nov 10, 2023 07:00AM
Oct 12, 2023 08:00AM
Sep 19, 2023 08:03AM
Aug 10, 2023 04:15PM
May 12, 2023 08:00AM IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Apr 25, 2023 08:02AM
Apr 25, 2023 08:00AM
Mar 30, 2023 04:15PM
Jan 5, 2023 07:03AM
Jan 5, 2023 07:00AM
Dec 8, 2022 07:07AM
Dec 8, 2022 07:00AM IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
Nov 10, 2022 07:30AM
Aug 12, 2022 04:17PM
Aug 12, 2022 04:15PM
Jul 12, 2022 08:00AM
Apr 13, 2022 08:30AM
Mar 28, 2022 08:04AM
Mar 28, 2022 08:00AM IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Jan 6, 2022 07:00AM
Jan 6, 2022 07:00AM
Dec 16, 2021 07:04AM
Dec 16, 2021 07:00AM
Nov 16, 2021 07:02AM
Nov 16, 2021 07:00AM
Oct 27, 2021 07:04AM IN8bio, Inc (INAB) Announces Publication of Preclinical Results of Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide
Oct 27, 2021 07:00AM

323,577 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All